Garden of Eve

To: Cannabis Licensees and Stakeholders Fr: Board Chair David Postman Re: Settlement with Unicorn Brands LLC  I am writing to follow up on an issue brought to the board’s attention by some of you and that many licensees expressed concerns about at Board meetings since last year.  When there is an open investigation and adjudication Read the full article... http://dlvr.it/SZD8LL

BORDEAUX, France--(BUSINESS WIRE)--Regulatory News: Aelis Farma (ISIN: FR0014007ZB4 - ticker: AELIS, PEA-PME eligible), a clinical-stage biopharmaceutical company specialized in the development of treatments for brain diseases, today announces that its half-year financial report has been made available to the public and filled with the French Financial Markets Authority (Autorité des marchés financiers). It can be consulted on the Company's website, www.aelisfarma.com, in the section Investors/Documentation/Reports. *** About AELIS FARMA Founded in 2013, Aelis Farma is a biopharmaceutical company that is developing a new class of drugs, the Signaling Specific inhibitors of the CB1 receptor of the endocannabinoid system (CB1-SSi). These new molecular entities hold great potential in the treatment of many brain diseases. CB1-SSi were developed by Aelis Farma on the basis of the discovery of a new natural defense mechanism of the brain made by the team of Dr. Pier Vincenzo Piazza...

Turn On. Tune In. Catch the Buzz on Marijuana Channel One. 

BORDEAUX, France--(BUSINESS WIRE)--Regulatory News: Aelis Farma (Paris: AELIS)(ISIN: FR0014007ZB4 - ticker: AELIS, PEA-PME eligible), a clinical-stage biopharmaceutical company specialized in the development of treatments for brain diseases, today announces its half-year results for the period ended June 30, 2022 and takes stock of its development. Pier Vincenzo Piazza, CEO of Aelis Farma, said: "We are very happy with the progress made during the first months of our listing on Euronext. Raising €25.3 million during our IPO in February allowed us to considerably strengthen our financial structure and be able to deploy our strategy with a high visibility. In accordance with the roadmap presented to the financial community, we have reached an important milestone with the recruitment of the first patient in the phase 2b study with Aelis Farma most advanced compound: AEF0117 for the treatment of cannabis addiction. The second part of the year promises to be just as dynamic, in parti...

CALGARY, Alberta--(BUSINESS WIRE)--High Tide Inc. (“High Tide” or the “Company”) (Nasdaq: HITI) (TSXV: HITI) (FSE: 2LYA), a leading retail-focused cannabis company with bricks-and-mortar as well as global e-commerce assets, is pleased to announce that it has ranked 21st out of 430 companies on the 2022 Report on Business ranking of Canada’s Top Growing Companies. Canada’s Top Growing Companies ranks Canadian companies based on their three-year revenue growth. High Tide earned its spot with a three-year growth rate of 1,970%. This follows the Company’s 2021 ranking of 82nd out of 448 companies with a three-year growth rate of 733%. “The Globe and Mail, Canada’s newspaper of record, has, for the second year in a row, recognized High Tide’s exponential growth, ranking us 21st out of 430 on its annual ranking of Canada’s Top Growing Companies due to our three-year revenue growth rate of 1,970%. Receiving this honour two years running is a testament to our ability to continue to execute ...

DUBLIN--(BUSINESS WIRE)--The "Cannabis Extract Market Size, Share & Trends Analysis Report by Product Type (Oil, Tinctures), by Extract Type (Full Spectrum Extracts, Cannabis Isolates), by Sources (Hemp. Marijuana), by End Use, by Region, and Segment Forecasts, 2022-2030" report has been added to ResearchAndMarkets.com's offering. The global cannabis extract market size is expected to reach USD 15.5 billion by 2030. according to this report, it is expected to expand at a CAGR of 20.6% over the forecast period. The growth is attributed to the rising usage of cannabis for recreational and medical purposes. Various nations have legalized cannabis usage which has reduced the sale in the black market and increased legal product purchases. The industry has also opened revenue-generating opportunities for various countries through government-imposed taxes on cannabis oil and tinctures that are commonly used to treat various ailments, including anxiety, nausea, and cancer. ...

DUBLIN–(BUSINESS WIRE)–The “Medicinal Cannabis Market, by Point of Sale, by Active Ingredient, and by Therapeutic Application, and by Region – Size, Share, Outlook, and Opportunity Analysis, 2022 – 2030” report has been added to ResearchAndMarkets.com’s offering. Medicinal cannabis, also known as medical marijuana, is used either for the treatment of diseases or to improve their Read the full article... http://dlvr.it/SYnpzW